Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Cardiovascular Cardiology Clinical Trials

ACC 2018 Preview: Zoll's LifeVest, Abbott's HeartMate 3 And Amplatzer, Late-Breaking Trial Devices

  • News

Executive Summary

New clinical data with the potential to change clinical practice will be presented at the 2018 American College of Cardiology Scientific Session and Expo in Orlando, Fla., Mar. 10-12. Among the planned late-breaking trials and featured research presentations is a study of Zoll's LifeVest wearable external cardioverter-defibrillator following a heart attack; new results from a trial of Abbott's Amplatzer PFO-closure device, and long-term data on Abbott's HeartMate 3 ventricular assist device.

Table

View full table

Advertisement

Related Content

Medtech Insight
iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis
Medtech Insight
More from ACC 2018: MOMENTUM 3, DEFENSE PFO
Medtech Insight
Mixed Results Of Zoll's LifeVest Trial Sparks Reaction From Cardiologists
Medtech Insight
US FDA Approves Medtronic's HVAD For Destination Therapy
Medtech Insight
Positive Long-Term Data Plug Doubts Over PFO-Closure Stroke Benefits
Medtech Insight
US Approvals Analysis: Abbott Leads Another Strong Month For Novel Approvals

Topics

Related Companies

Advertisement
Tags:
Cardiovascular Cardiology Clinical Trials
UsernamePublicRestriction

Register

MT122111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By